Skip to content
Peptigraph home

AMAZE 1: Amycretin Phase 3 trial (NCT07339423)

Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Obesity (AMAZE 1)

Registry record checked

At a glance

Phase
Phase 3
Status
Recruiting
Enrolment
1,150
estimated
Start
24 Feb 2026 (actual)
Primary completion
26 Jun 2029 (estimated)
Sponsor
Novo Nordisk A/S
Design

Arms and doses

NCT07339423 study arms
ArmTypeInterventionsDescription
NNC0487-0111ExperimentalDrug: NNC0487-0111Participants will be randomized to receive 1 out of 4 different dose levels subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.
PlaceboPlacebo comparatorDrug: Placebo (matched to NNC0487-0111)Participants will receive placebo matched to NNC0487-0111 subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.
Endpoints

Primary endpoint

NCT07339423 primary outcomes
MeasureTime frame
Relative change in body weightFrom baseline (week 0) to week 84
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT07339423 secondary outcomes
MeasureTime frame
Change in waist circumferenceFrom baseline (week 0) to week 84 and week 136
Change in systolic blood pressure (SBP)From baseline (week 0) to week 84 and week 136
Change in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) physical function scoreFrom baseline (week 0) to week 84 and week 136
Change in SF-36v2® Health Survey Acute (SF-36v2 Acute) physical functioning scoreFrom baseline (week 0) to week 84 and week 136
Change in body weightFrom baseline (week 0) to week 84 and week 136
Change in body mass index (BMI)From baseline (week 0) to week 84 and week 136
Change in IWQOL-Lite-CT physical composite scoreFrom baseline (week 0) to week 84 and week 136
Change in IWQOL-Lite-CT psychosocial composite scoreFrom baseline (week 0) to week 84 and week 136
Change in IWQOL-Lite-CT total scoreFrom baseline (week 0) to week 84 and week 136
Change in glycated haemoglobin (HbA1c)From baseline (week 0) to week 84 and week 136
Change in fasting plasma glucose (FPG)From baseline (week 0) to week 84 and week 136
Ratio to baseline: change in fasting insulinFrom baseline (week 0) to week 84 and week 136
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
Not stated
Results

Results

No results posted on ClinicalTrials.gov as of 2 Oct 2026.

Sources

  1. 1Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Obesity (AMAZE 1)ClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026

Found an error? Report a correction.